Menu
Search
|

Menu

Close
X

Otonomy Inc OTIC.OQ (NASDAQ Stock Exchange Global Select Market)

2.75 USD
-- (--)
As of Mar 22
chart
Previous Close 2.75
Open --
Volume --
3m Avg Volume 31,397
Today’s High --
Today’s Low --
52 Week High 4.85
52 Week Low 1.50
Shares Outstanding (mil) 30.30
Market Capitalization (mil) 104.55
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
1
FY16
1
EPS (USD)
FY18
-1.645
FY17
-2.975
FY16
-3.691
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
81.80
8.39
Price to Book (MRQ)
vs sector
0.70
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
0.00
16.02
LT Debt to Equity (MRQ)
vs sector
0.00
11.35
Return on Investment (TTM)
vs sector
-53.30
13.82
Return on Equity (TTM)
vs sector
-53.63
15.24

EXECUTIVE LEADERSHIP

Jay Lichter
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
David Weber
President, Chief Executive Officer, Director, Since
Salary: $530,000.00
Bonus: $127,200.00
Paul Cayer
Chief Financial and Business Officer, Since 2015
Salary: $383,675.00
Bonus: $61,388.00
Robert Savel
Chief Technical Officer, Since 2014
Salary: --
Bonus: --
Kathie Bishop
Chief Scientific Officer, Since 2017
Salary: $321,458.00
Bonus: $102,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4796 Executive Dr
SAN DIEGO   CA   92121-3090

Phone: +1619.3232200

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.

SPONSORED STORIES